Changeflow GovPing Pharma & Drug Safety ONO Pharmaceutical ABHD6 Antagonist Patent US12...
Routine Rule Added Final

ONO Pharmaceutical ABHD6 Antagonist Patent US12600730B2

Favicon for changeflow.com USPTO Patent Grants - Organic Chemistry (C07D)
Published
Detected
Email

Summary

USPTO granted Patent US12600730B2 to ONO Pharmaceutical Co., Ltd. on April 14, 2026, covering substituted cyclopenta[c]pyrrole compounds as ABHD6 antagonists for pharmaceutical use. The patent includes 18 claims for compounds useful in preventing or treating diseases associated with ABHD6 enzyme inhibition. The application was filed on April 8, 2024.

What changed

USPTO granted patent protection for ONO Pharmaceutical's ABHD6 antagonist compounds (substituted cyclopenta[c]pyrroles) with 18 claims covering the pharmaceutical compositions and methods of use. The patent claims priority from Application No. 18629648 filed April 8, 2024.

For pharmaceutical manufacturers and biotech companies developing metabolic or neurological therapeutics targeting the ABHD6 enzyme pathway, this patent establishes prior art and may necessitate licensing negotiations or alternative compound design strategies to avoid infringement.

What to do next

  1. Monitor patent portfolio for potential licensing opportunities
  2. Review freedom-to-operate for ABHD6 inhibitor development programs

Archived snapshot

Apr 15, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Substituted cyclopenta[c]pyrroles as ABHD6 antagonists

Grant US12600730B2 Kind: B2 Apr 14, 2026

Assignee

ONO PHARMACEUTICAL CO., LTD.

Inventors

Atsushi Yoshida, Ryuichi Hyakutake, Nozomu Nagashima, Ryosuke Misu, Shohei Mori

Abstract

A drug is provided, which contains, as an active ingredient, a compound having ABHD6 inhibitory activity in prevention and/or treatment of a disease associated with ABHD6. A compound of formula (I-A) or a pharmaceutically acceptable salt thereof has ABHD6 inhibitory activity and therefore is useful as a pharmaceutical ingredient having potent ABHD6 inhibitory activity in the prevention and/or treatment of a disease associated with ABHD6:
in which all symbols represent the same meaning as the symbols described in the specification.

CPC Classifications

A61K 31/403 C07D 209/52

Filing Date

2024-04-08

Application No.

18629648

Claims

18

View original document →

Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 14th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12600730B2

Who this affects

Applies to
Pharmaceutical companies Medical device makers Clinical investigators
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Patent grants Drug compound development Pharmaceutical research
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare Biotechnology

Get alerts for this source

We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!